Correlation Between Cidara Therapeutics and Puma Biotechnology

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Cidara Therapeutics and Puma Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cidara Therapeutics and Puma Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Cidara Therapeutics and Puma Biotechnology, you can compare the effects of market volatilities on Cidara Therapeutics and Puma Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cidara Therapeutics with a short position of Puma Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cidara Therapeutics and Puma Biotechnology.

Diversification Opportunities for Cidara Therapeutics and Puma Biotechnology

0.65
  Correlation Coefficient

Poor diversification

The 3 months correlation between Cidara and Puma is 0.65. Overlapping area represents the amount of risk that can be diversified away by holding Cidara Therapeutics and Puma Biotechnology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Puma Biotechnology and Cidara Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cidara Therapeutics are associated (or correlated) with Puma Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Puma Biotechnology has no effect on the direction of Cidara Therapeutics i.e., Cidara Therapeutics and Puma Biotechnology go up and down completely randomly.

Pair Corralation between Cidara Therapeutics and Puma Biotechnology

Given the investment horizon of 90 days Cidara Therapeutics is expected to generate 1.15 times more return on investment than Puma Biotechnology. However, Cidara Therapeutics is 1.15 times more volatile than Puma Biotechnology. It trades about 0.23 of its potential returns per unit of risk. Puma Biotechnology is currently generating about 0.07 per unit of risk. If you would invest  1,180  in Cidara Therapeutics on September 14, 2024 and sell it today you would earn a total of  1,108  from holding Cidara Therapeutics or generate 93.9% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Cidara Therapeutics  vs.  Puma Biotechnology

 Performance 
       Timeline  
Cidara Therapeutics 

Risk-Adjusted Performance

17 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Cidara Therapeutics are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of fairly inconsistent basic indicators, Cidara Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.
Puma Biotechnology 

Risk-Adjusted Performance

5 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Puma Biotechnology are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite fairly unsteady basic indicators, Puma Biotechnology demonstrated solid returns over the last few months and may actually be approaching a breakup point.

Cidara Therapeutics and Puma Biotechnology Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Cidara Therapeutics and Puma Biotechnology

The main advantage of trading using opposite Cidara Therapeutics and Puma Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cidara Therapeutics position performs unexpectedly, Puma Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Puma Biotechnology will offset losses from the drop in Puma Biotechnology's long position.
The idea behind Cidara Therapeutics and Puma Biotechnology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Other Complementary Tools

Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Money Managers
Screen money managers from public funds and ETFs managed around the world
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance